A Phase 3 interventional study of methylcobalamin and saline solution in Amyotrophic Lateral Sclerosis, sponsored by Eisai Co., Ltd.. Completed at 16 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by Eisai Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan — 2 open to participants now, 4 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Japan.
Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2017, is one of 8 in phase 3, and was the 9th registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →2 of the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan are open now. Recruiting first, the newest first:
National Center of Neurology and Psychiatry, Japan · Sites in Japan
Ages 20+
Regeneron Pharmaceuticals · Sites in Japan, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 10
First in 2007; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 136 across the 20 interventional studies, 24 across the 1 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 21 have an industry lead sponsor. The 10 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Eisai Co., Ltd. has 3 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Amyotrophic Lateral Sclerosis with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To examine the clinical efficacy and safety of ultra-high dose (50mg, im, twice a week) methylcobalamin in retarding the progression of symptoms in amyotrophic lateral sclerosis (ALS) patients, we enroll ALS patients diagnosed by Updated Awaji Criteria within 12 months after the clinical onset. First they are followed for 12 weeks with Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) scores, and only those who exhibit drops of 1-2 points are allowed to enter into the test period. A total of 128 patients are randomized and the half having placebo. They are blindly evaluated for drops of ALSFRS-R in 16 weeks, as the primary outcome. After this, all subjects receive methylcobalamin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Treatment and OLE Phase:
Tsunagi Phase:
Exclusion Criteria:
Treatment and OLE Phase:
Tsunagi Phase:
Not applicable.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intramuscular injection of saline solution
Drug: saline solution
intramuscular injection of methylcobalamin
Drug: methylcobalamin
intramuscular injection of methylcobalamin
Drug: methylcobalamin
intramuscular injection of methylcobalamin
Drug: methylcobalamin
Patients receive methylcobalamin 50mg intramuscular injection twice a week.
Patients receive saline solution intramuscular injection twice a week.
Treatment Phase: ALSFRS-R
Drop of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (maximum or normal 48 and minimum 0; higher values represent better condition)
Time frame: during 16 weeks of test period
Treatment Phase: time to event
time from the randomization to the onset of any of the event (24-hour use of noninvasive respiratory support, use of invasive respiratory support, or death)
Time frame: during 16 weeks of test period
Treatment Phase: %Functional Vital Capacity (FVC)
changes of per cent Functional Vital Capacity
Time frame: during 16 weeks of test period
Treatment Phase: homocystein
changes of serum levels of homocystein
Time frame: during 16 weeks of test period
Treatment Phase: Manual Muscle Testing (MMT)
changes of sum of Medical Research Council scales of manual muscle testing, ranging 5 (normal), 4, 4+, 3, 2, 1, 0 (minimal) ( for analysis each is converted to 6, 5, 4, 3, 2, 1, 0) of the 11 muscles in the limbs (5x2) and neck(1)
Time frame: during 16 weeks of test period
Treatment Phase: Norris scale
changes of Norris scale (39 normal - 0 worst)
Time frame: during 16 weeks of test period
Treatment Phase: Grip Power
changes of sum of grip power in kilograms on both sides
Time frame: during 16 weeks of test period
Treatment Phase: 40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40)
changes of sum of ALSAQ-40 (40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire) score (40 normal - 200 worst)
Time frame: during 16 weeks of test period
Treatment Phase: safety
any adverse events during the treatment period
Time frame: during 16 weeks of test period
OLE Phase: time to event
time from the randomization to the onset of any of the event (24-hour use of noninvasive respiratory support, use of invasive respiratory support, or death)
Time frame: up to 6 years 11 months
OLE Phase: ALSFRS-R
Drop of ALSFRS-R Scale-Revised (maximum or normal 48 and minimum 0; higher values represent better condition)
Time frame: up to 6 years 11 months
OLE Phase: safety
any adverse events during the OLE period including laboratory tests and vital signs assessment.
Time frame: up to 6 years 11 months
Tsunagi Phase: time to event
time period from drug assignment to any of the event (24-hour use of noninvasive respiratory support, use of invasive respiratory support, or death)
Time frame: up to 6 months
Tsunagi Phase: ALSFRS-R
Drop of ALSFRS-R Scale-Revised (maximum or normal 48 and minimum 0; higher values represent better condition)
Time frame: up to 6 months
Tsunagi Phase: safety
any adverse events during the Tsunagi phase including laboratory tests and vital signs assessment.
Time frame: up to 6 months
Plan to share: Yes — anonymous data are available
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: from October 1, 2017 till March 31, 2020
Access criteria: those who have approval from Institutional Review Board (IRB)
Data sharing details ↗ · als-mecobalamin.org
Ran from Nov 2017 to primary completion in Feb 2020, 27 months.
Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 27 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mecobalamin
Amyotrophic Lateral Sclerosis →